Eli Lilly and Co (LLY.US) weight loss drug breakthrough! Research shows that tirzepatide can significantly reduce the risk of heart failure.
eli lilly and co's flagship weight loss drug Zepbound and diabetes treatment drug Mounjaro's active ingredient Tirzepatide can significantly reduce the risk of worsening heart failure in obese adults with heart failure with preserved ejection fraction (HFpEF).
Eli Lilly and Co (LLY.US) potential groundbreaking oral small molecule significantly reduces cardiovascular events in high-risk adults with elevated Lp(a) levels.
Ruth Gimeno, Vice President of the Diabetes and Metabolic Research Group at eli lilly and co, stated: "We are pleased to see these promising results and look forward to further exploring the next steps for muvalaplin."
Evercore Maintains Eli Lilly and Co(LLY.US) With Hold Rating
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $1,010
Express News | Astrazeneca, eli lilly and co, and other funds have invested in Chengyuan Technology.
Weight-reducing version of semaglutide lands in the Chinese market! Novo Nordisk (NVO.US) unlocks new growth engine.
novo-nordisk a/s launched Wegovy in china at a price lower than in the usa; this is an important step for the company to increase its investment in the rapidly growing market in china.